Brief: Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data And Additional Subset Analysis

Nicox SA

03/07/2023 06:41

July 3 (Reuters) - Nicox SA  ALCOX.PA :
    * PRESENTED NCX 470 PHASE 3 MONT BLANC ADAPTIVE DESIGN DATA
AND
ADDITIONAL SUBSET ANALYSIS SHOWING SUPERIORITY OVER LATANOPROST
AT THE WORLD GLAUCOMA CONGRESS
    * NCX 470 0.1% SHOWED UP TO 1.73MMHG GREATER MEAN DIURNAL
INTRAOCULAR PRESSURE ( IOP ) REDUCTION FROM BASELINE THAN
LATANOPROST IN ADAPTIVE DOSE SELECTION PERIOD OF PHASE 3 MONT
BLANC TRIAL
    * NCX 470 DEMONSTRATED A STATISTICALLY GREATER PROPORTION OF
SUBJECTS WITH 10 MMHG OR MORE IOP REDUCTION COMPARED TO
LATANOPROST IN MONT BLANC TRIAL

Source text for Eikon:  ID:nGNE2dFV1B 
Further company coverage:  ALCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))